Economy · World
Novo Nordisk Rebrands to Novo Amid Obesity Market Competition
Danish pharmaceutical company Novo Nordisk has rebranded its corporate identity to 'Novo' as part of a strategic move to strengthen its position in the competitive obesity market. The company, known for its diabetes and obesity medications like Ozempic, is undergoing corporate changes to support its growth and market focus. This rebranding signifies Novo's commitment to expanding its presence and innovation in the therapeutic area of obesity treatment.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): CNBC, South China Morning Post